No Data
China Resources Pharmaceutical Group's Subsidiary Expects Higher Attributable Profit in 2024
CHINARES PHARMA (03320.HK): China Resources Boya Bio-pharmaceutical Group's Net income for 2024 is expected to be between 0.38 billion and 0.48 billion yuan.
Glory Financial reported on January 22 that CHINARES PHARMA (03320.HK) announced that on January 22, 2025, China Resources Boya Bio-pharmaceutical Group will publish its performance forecast for the year ending December 31, 2024. According to this announcement, the net income attributable to the shareholders of China Resources Boya Bio-pharmaceutical Group for the year ending December 31, 2024, is expected to be between approximately RMB 380 million and RMB 480 million (compared to approximately RMB 237.46 million in net income for the same period last year), while the net income attributable to the shareholders of China Resources Boya Bio-pharmaceutical Group after deducting non-recurring gains and losses is expected to be between approximately RMB 283.74 million and RMB.
Liberal Arts Biotech: 2024 Annual Results Forecast
China Resources Boya Bio-Pharmaceutical Gets Nod to Set Up Blood Collection Station
China Resources Boya Bio-pharmaceutical Group (300294.SZ) has been approved to set up a blood plasma collection station in Inner Mongolia ERDOS Resources Dalad Banner.
China Resources Boya Bio-pharmaceutical Group (300294.SZ) announced that the company received notice from the Inner Mongolia Autonomous Region Health...
CHINARES PHARMA (03320) subsidiary CHINARES PHARMA Holdings' Shareholding in China Resources Boya Bio-pharmaceutical Group has reached 1%.
CHINARES PHARMA (03320) announced that between November 8, 2024, and December 18, 2024, public...
Some Confidence Is Lacking In China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294) As Shares Slide 26%
